Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
55.64M | 52.55M | 45.56M | 48.30M | 41.98M | Gross Profit |
33.11M | 29.46M | 21.35M | 27.71M | 25.42M | EBIT |
-13.64M | -22.84M | -40.55M | -24.07M | -15.19M | EBITDA |
-11.14M | -19.15M | -43.11M | -23.10M | -13.65M | Net Income Common Stockholders |
-15.12M | -23.69M | -47.39M | -26.85M | -16.69M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
22.04M | 36.49M | 62.39M | 99.44M | 57.45M | Total Assets |
44.69M | 56.94M | 86.22M | 123.44M | 78.38M | Total Debt |
3.18M | 23.72M | 34.50M | 27.48M | 26.66M | Net Debt |
-18.85M | -12.77M | -27.89M | -71.96M | -30.79M | Total Liabilities |
35.15M | 34.25M | 43.76M | 38.51M | 36.54M | Stockholders Equity |
9.54M | 22.69M | 42.46M | 84.94M | 41.84M |
Cash Flow | Free Cash Flow | |||
-13.79M | -15.29M | -36.46M | -22.64M | -14.54M | Operating Cash Flow |
-13.28M | -14.46M | -32.14M | -20.27M | -14.08M | Investing Cash Flow |
-515.00K | -804.00K | -4.32M | -2.42M | -455.00K | Financing Cash Flow |
-663.00K | -10.63M | -489.00K | 64.68M | -97.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $76.25M | ― | -93.78% | ― | 5.89% | 38.12% | |
52 Neutral | $28.75M | ― | -51.22% | ― | -10.56% | 41.02% | |
52 Neutral | $5.38B | 3.59 | -41.63% | 2.87% | 17.72% | 1.87% | |
51 Neutral | $89.10M | ― | -345.31% | ― | 28.29% | 23.11% | |
42 Neutral | $83.87M | ― | -337.30% | ― | 45.30% | 45.67% | |
36 Underperform | $110.75M | ― | -55.78% | ― | -74.84% | 14.63% | |
29 Underperform | $46.66M | ― | 138.92% | ― | 59.10% | 37.59% |
On April 25, 2025, Exagen Inc. entered into a Credit Agreement with Perceptive Credit Holdings IV, LP, securing a senior secured delayed draw term loan facility of up to $75 million, with an initial $25 million tranche funded to refinance existing debt and extend the maturity. This strategic financial move is aimed at strengthening Exagen’s balance sheet and providing growth capital, allowing the company to further its leadership in autoimmune testing solutions and enhance patient care. The agreement includes additional tranches contingent on revenue and business development milestones, with the loan secured by Exagen’s assets and accompanied by a warrant to purchase shares of Exagen’s common stock.
Spark’s Take on XGN Stock
According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.
Exagen’s stock is moderately attractive with a score of 56. Key strengths include record revenue growth and strategic advancements highlighted in the earnings call, which anticipate positive adjusted EBITDA. However, ongoing net losses, negative cash flows, and valuation challenges dampen the outlook. Improvements in financial stability and achieving profitability are critical for enhancing the stock’s attractiveness.
To see Spark’s full report on XGN stock, click here.